1ZP2MA

{{cs1 config|name-list-style=vanc|display-authors=6}}

{{Infobox drug

| drug_name =

| image = 1ZP2MA.svg

| width =

| caption =

| pronounce =

| tradename =

| Drugs.com =

| MedlinePlus =

| licence_CA =

| licence_EU =

| DailyMedID =

| licence_US =

| pregnancy_AU =

| pregnancy_category =

| dependency_liability =

| addiction_liability =

| routes_of_administration =

| class = Monoamine releasing agent

| ATC_prefix =

| ATC_suffix =

| legal_status =

| bioavailability =

| protein_bound =

| metabolism =

| metabolites =

| onset =

| elimination_half-life =

| duration_of_action =

| excretion =

| CAS_number =

| CAS_supplemental =

| PubChem = 168256424

| PubChemSubstance =

| IUPHAR_ligand =

| DrugBank =

| ChemSpiderID =

| UNII =

| KEGG =

| ChEBI =

| ChEMBL =

| NIAID_ChemDB =

| PDB_ligand =

| synonyms = [1-(Indolizin-1-yl)propan-2-yl](methyl)amine; 1-(Indolizin-1-yl)-N-methylpropan-2-amine; Compound 26-5; Indolizine-NM-AMT; Indolizine-NM-αMT

| IUPAC_name = 1-indolizin-1-yl-N-methylpropan-2-amine

| C=12 | H=16 | N=2

| SMILES = CC(CC1=C2C=CC=CN2C=C1)NC

| StdInChI = 1S/C12H16N2/c1-10(13-2)9-11-6-8-14-7-4-3-5-12(11)14/h3-8,10,13H,9H2,1-2H3

| StdInChIKey = FMOIPWVAARKPNM-UHFFFAOYSA-N

}}

1ZP2MA, also known as [1-(indolizin-1-yl)propan-2-yl](methyl)amine or as 1-(indolizin-1-yl)-N-methylpropan-2-amine, is a monoamine releasing agent and an indolizine derivative.{{cite patent | country=WO | number=2023183613A2 | inventor= Baggott MJ | status=patent | title=Indolizine compounds for the treatment of mental disorders or inflammation | pubdate=2023 September 28 | gdate= | fdate=24 March 2023 | pridate=24 March 2023 | assign1=Tactogen | url=https://patents.google.com/patent/WO2023183613A2/ | quote=BRIEF DESCRIPTION OF THE FIGURES FIG. 1 is a concentration-response curve for compound 26-5 HCl when tested in the Dopamine Release Assay in rat synaptosomes as described in Example 12. [...] Synthesis of 1-(indolizin-1-yl)-N-methylpropan-2-amine HCl salt (26-5 HCl): [...] EXAMPLE 12: Dopamine Release Assay [1-(indolizin-1-yl)propan-2-yl](methyl)amine (1ZP2MA) HCl salt (26-5 HCl), 1- (indolizin-1-yl)butan-2-amine (1ZB2A) HCl salt (27-1 HCl), and [1-(indolizin-1-yl)butan-2- yl](methyl)amine (1ZB2MA) HCl salt (25-14 HCl) were assayed for dopamine release in rat synaptosomes [...] All three compounds showed ability to release dopamine, with EC50s for 26-5, 27-1, and 25-14 estimated as 0.0619, 21.8, 2.71 µM, respectively (Figures 1, 2, and 3 respectively). }} It is the analogue and positional isomer of the stimulant-like drug α,N-dimethyltryptamine (α,N-DMT or N-methyl-α-methyltryptamine (N-methyl-αMT)) in which the indole ring has been replaced with an indolizine ring. 1ZP2MA has been found to be a potent dopamine releasing agent, with an {{Abbr|EC₅₀|half-maximal effective concentration}} of 62{{nbsp}}nM. It is the α-methyl and N-desmethyl analogue of (2-(indolizin-1-yl)ethyl)dimethylamine (TACT908; the indolizine analogue of dimethyltryptamine (DMT)). 1ZP2MA and 2ZEDMA were patented by Tactogen in 2023.